- Schizophrenia:
- IM 234mg on day 1, then 156mg on day 8
- Recommended maintenance dose is IM 117mg once monthly
- Some patients may require lower or higher dosages (monthly dose range 39-234mg)
- Pre-filled syringe:
- 78mg
- 117mg
- 156mg
- 234mg
- Tablet:
- 6mg
- Shake prefilled syringe vigorously for at least 15 seconds within 5 minutes before administration to ensure a homogeneous suspension
- Injected into deltoid
2nd generation antipsychotic
Major active metabolite of risperidone. The exact mechanism is unknown but it is thought to antagonize dopamine D2 receptors and serotonin 5-HT2A receptors
- Injection site reaction
- Increased weight
- Headache
- Parkinsonism
- Hyperkinesia
- URTI
- Akathisia
- Tremor
- Dystonia
- Hypersensitivity to components
- CrCl <10
- Congenital long QT syndrome
- History of arrhythmia
WARNING
Elderly patients with dementia-related psychosis treated with antipsychotic drugs have a higher mortality rate
- Risperidone
- Amisulpride
- Goserelin
- Leuprolide
- Cisapride
- Levoketoconazole
- Pimozide
- Thioridazine
- Dronedarone
Drug Status
| Availability | Prescription only |
| Pregnancy | Category C |
| Breastfeeding | Contraindicated |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Invega | 6mg | Tablet | 28’s | Janssen-Cilag | Phillips Therapeutics |
| Invega Sustenna | 78mg | Pre-filled Syringe | 1’s | Janssen-Cilag | Phillips Therapeutics |
| Invega Sustenna | 156mg | Pre-filled Syringe | 1’s | Janssen-Cilag | Phillips Therapeutics |
| Invega Sustenna | 234mg | Pre-filled Syringe | 1’s | Janssen-Cilag | Phillips Therapeutics |
| Invega Sustenna | 117mg | Pre-filled Syringe | 1’s | Janssen-Cilag | Phillips Therapeutics |